Exposing explant cultures of latently infected mouse trigeminal ganglia alternately to acyclovir-containing and drug-free medium led to a significant decrease in the proportion of ganglia containing reactivatable herpes simplex virus. The loss of virus from the explant cultures was not caused by thermal inactivation during prolonged incubation periods. The efficiency of virus elimination may depend on the frequency and duration of the alternating treatment and on the number of latently infected neurons in the ganglia.
Acute ganglionic herpes simplex virus (HSV) infections can be prevented with acyclovir (ACV) (2, 7) , but latent infections in animals are not affected by this drug (1-3, 6, 9-11). Field and Wildy (4) concluded that "attempts to eradicate the latent infection during the quiescent phase are likely to be fruitless and these drugs should not be used for this purpose." An alternative to eliminating latent virus during the quiescent phase is eradicating the virus during the early stages of reactivation. One means to this end is to create conditions permitting the interaction of ACV with HSV*induced thymidine kinase before mature virions are assembled (5) . In a previous study, explant cultures of latently infected ganglia were maintained for 6 or 24 h in a drug-free medium and then in ACV-containing medium for 4 days and sonicated after another 4 days in drug-free medium. At the end of the experiment, all homogenates of the ganglia contained virus, despite the fact that ACV .was added only after reactivation was initiated by explanting the ganglia in drug-free medium for 6 or 24 h (6). Similar results were obtained by Park et al. (8) , who suggested that under these conditions ACV may eliminate at least a part of the ganglionic viral reservoir.
The failure of this experiment, as well as of similar ones in which incubation with ACV was extended to 8 or 12 days (5), suggests that either HSV was not reactivated during the 6-or 24-h preincubation period or it was already reactivated and assembled and therefore no longer influ- enced by incubation with ACV. The experiments also suggested that the initiation of HSV reactivation in explant cultures of latently infected ganglia is an asynchronous process and therefore that it would be difficult to achieve perfect timing for successful interaction between antiviral drugs and virus-induced enzymes. Another difficulty is that the number of latently infected neurons in the ganglia of experimentally inoculated animals is highly variable and cannot be standardized even under controlled experimental procedures (12).
To circumvent some of these problems, we exposed explant cultures of latently infected ganglia to discontinuous ACV treatment. Latently infected trigeminal ganglia were obtained from hairless mice killed 4 to 6 weeks after being inoculated in the orofacial area with HSV type 1, strain S (6).
This experiment required prolonged maintenance of latently infected ganglia in explant cultures. Since gradual thermoinactivation of the reactivated virus may take place during this period, we determined virus titers in trigeminal ganglia maintained for up to 17 days in explant culture. At the indicated intervals, the ganglia explants and culture media were sonicated and centrifuged. The virus titer of the supernatant was determined by a plaque assay: duplicate plates with confluent growth of Vero cells were inoculated with serial 10-fold dilutions of the supernatant and overlaid with Eagle minimal essential medium (MEM) containing 2% fetal bovine serum and 2% methylcellulose. After 4 days of incubation at 37°C, the cell layer was stained with neutral red and the plaques were counted.
The mean titer of reactivated HSV in explant ANTIMICROB. AGENTS CHEMOTHER. cultures of latently infected mouse trigeminal ganglia increased for up to 9 days (Fig. 1) ). At the end of the incubation period, the explant cultures were sonicated, and the supernatants of centrifuged ganglia homogenates were assayed for the presence of HSV. Controls consisted of ganglia maintained in MEM for the entire incubation period, ganglia maintained in the presence of ACV for the entire incubation period, and ganglia maintained for 14 days with ACV and then for 3 additional days in MEM.
At the end of 17 days of incubation in MEM, all of the ganglia contained high titers of reactivated virus (Table 1) . No explant culture maintained in the presence of ACV for 17 days had evidence of reactivated virus. Of 18 ganglia explant-cultures maintained for 14 days in the presence of ACV and then for 3 days in MEM, 8 showed evidence of reactivated virus. One explanation for the absence of HSV in some of these ganglia is the prolonged time of incubation with ACV. A similar reduction in the number of HSV-containing ganglia after incubation with ACV was observed also by others (8) . It is likely that even in the presence of ACV a gradual reactivation of latent HSV takes place in the neurons, and the interaction of HSV-induced thymidine kinase with ACV leads to irreversible interruption of viral DNA synthesis. When latently infected ganglia were alternated twice between incubation in drug-free and ACVcontaining media, the occurrence of ganglia with reactivated virus was reduced, but not to a statistically significant extent. When the incubation conditions were alternated four times, the number of ganglia with reactivated virus was decreased significantly (P < 0.0001) ( Table 1) .
The experiments suggested that frequently switching explant cultures of latently infected ganglia from drug-free to ACV-containing medium can lead to a significant decrease in the proportion of ganglia containing reactivatable virus. As control ganglia cultures showed high titers of reactivated virus even after prolonged incubation, it is unlikely that elimination of latent HSV in the presence of ACV was achieved only by thermal inactivation. A possible interaction between ACV and HSV-induced thymidine kinase may lead to the gradual elimination of reactivatable HSV.
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